WO2001025438A3 - Homologues d'interferons alpha - Google Patents

Homologues d'interferons alpha Download PDF

Info

Publication number
WO2001025438A3
WO2001025438A3 PCT/US2000/027781 US0027781W WO0125438A3 WO 2001025438 A3 WO2001025438 A3 WO 2001025438A3 US 0027781 W US0027781 W US 0027781W WO 0125438 A3 WO0125438 A3 WO 0125438A3
Authority
WO
WIPO (PCT)
Prior art keywords
homologues
nucleic acids
polypeptides
ifn
methods
Prior art date
Application number
PCT/US2000/027781
Other languages
English (en)
Other versions
WO2001025438A2 (fr
Inventor
Volker Heinrichs
Teddy Chen
Phillip A Patten
Original Assignee
Maxygen Inc
Volker Heinrichs
Teddy Chen
Phillip A Patten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc, Volker Heinrichs, Teddy Chen, Phillip A Patten filed Critical Maxygen Inc
Priority to JP2001528590A priority Critical patent/JP2003511031A/ja
Priority to EP00970665A priority patent/EP1238082A2/fr
Priority to AU80013/00A priority patent/AU8001300A/en
Priority to CA002385045A priority patent/CA2385045A1/fr
Priority to MXPA02003492A priority patent/MXPA02003492A/es
Publication of WO2001025438A2 publication Critical patent/WO2001025438A2/fr
Publication of WO2001025438A3 publication Critical patent/WO2001025438A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

L'invention se rapporte à des homologues d'interférons alpha (à la fois acides nucléiques et polypeptides). Elle se rapporte également à des compositions contenant ces acides nucléiques et polypeptides d'homologues d'interférons, à des cellules recombinées comportant lesdits acides nucléiques polypeptides d'homologues d'interférons, à des méthodes de fabrication de ces nouveaux homologues et d'anticorps dirigés contre ces nouveaux homologues, et à des méthodes d'utilisation de ces homologues. L'invention se rapporte en outre à des systèmes intégrés comportant les séquences desdits acides nucléiques ou polypeptides.
PCT/US2000/027781 1999-10-07 2000-10-06 Homologues d'interferons alpha WO2001025438A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001528590A JP2003511031A (ja) 1999-10-07 2000-10-06 ＩＦＮ−αホモログ
EP00970665A EP1238082A2 (fr) 1999-10-07 2000-10-06 Homologues d'interferons alpha
AU80013/00A AU8001300A (en) 1999-10-07 2000-10-06 Ifn-alpha homologues
CA002385045A CA2385045A1 (fr) 1999-10-07 2000-10-06 Homologues d'interferons alpha
MXPA02003492A MXPA02003492A (es) 1999-10-07 2000-10-06 Homologos de interferon-alfa.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41518399A 1999-10-07 1999-10-07
US09/415,183 1999-10-07

Publications (2)

Publication Number Publication Date
WO2001025438A2 WO2001025438A2 (fr) 2001-04-12
WO2001025438A3 true WO2001025438A3 (fr) 2002-07-11

Family

ID=23644696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027781 WO2001025438A2 (fr) 1999-10-07 2000-10-06 Homologues d'interferons alpha

Country Status (8)

Country Link
EP (1) EP1238082A2 (fr)
JP (1) JP2003511031A (fr)
CN (1) CN1451045A (fr)
AR (1) AR025969A1 (fr)
AU (1) AU8001300A (fr)
CA (1) CA2385045A1 (fr)
MX (1) MXPA02003492A (fr)
WO (1) WO2001025438A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608445B1 (en) 1999-12-29 2009-10-27 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US7521216B2 (en) 1999-12-29 2009-04-21 Verenium Corporation Nitrilases and methods for making and using them
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
FR2822845B1 (fr) 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823763A1 (fr) * 2001-04-18 2002-10-25 Genodyssee Nouveaux polynucleotides et polypeptides de l'interferon alpha 6
FR2823764B1 (fr) * 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
FR2824333B1 (fr) * 2001-05-03 2003-08-08 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
FR2825716B1 (fr) 2001-06-11 2004-09-24 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 7
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
AU2003251523A1 (en) 2002-06-13 2003-12-31 Diversa Corporation Processes for making (r)-ethyl 4-cyano-3-hydroxybutyric acid
AU2003263552A1 (en) 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
CA2504267A1 (fr) * 2002-11-18 2004-06-03 Maxygen, Inc. Polypeptides et conjugues interferon-alpha
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
MXPA06013412A (es) 2004-05-19 2007-01-23 Maxygen Inc Polipeptidos de interferon-alfa y conjugados.
JP2008545393A (ja) * 2005-05-18 2008-12-18 マキシジェン， インコーポレイテッド 進歩したインターフェロンαポリペプチド
DK2115153T3 (da) 2007-03-01 2013-09-08 Bp Corp North America Inc Nitrilaser, nucleinsyrer som koder for dem og fremgangsmåder til at fremstille og anvende disse
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002457A1 (fr) * 1982-01-15 1983-07-21 Cetus Corp Interferon alpha 76
WO2000052153A2 (fr) * 1999-03-02 2000-09-08 Maxygen, Inc. Ligands delegues pour recepteur orphelins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801685A (en) * 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002457A1 (fr) * 1982-01-15 1983-07-21 Cetus Corp Interferon alpha 76
WO2000052153A2 (fr) * 1999-03-02 2000-09-08 Maxygen, Inc. Ligands delegues pour recepteur orphelins

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHANG C -C J ET AL: "EVOLUTION OF A CYTOKINE USING DNA FAMILY SHUFFLING", NATURE BIOTECHNOLOGY,NATURE PUBLISHING,US, vol. 17, no. 8, August 1999 (1999-08-01), pages 793 - 797, XP000946490, ISSN: 1087-0156 *
CRAMERI A ET AL: "DNA SHUFFLING OF A FAMILY OF GENES FROM DIVERSE SPECIES ACCELERATESDIRECTED EVOLUTION", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 391, 15 January 1998 (1998-01-15), pages 288 - 291, XP000775869, ISSN: 0028-0836 *
D.V. GOEDDEL ET AL: "The stucture of eight distinct cloned human leukocyte interferon cDNAs", NATURE, vol. 290, no. 5, 5 March 1981 (1981-03-05), pages 20 - 26, XP002055149 *
DATABASE EMBL 26 November 1990 (1990-11-26), E. GREN ET AL: "human leukocyte interferon-alpha mRNA, complete cds, clone pIFN9", XP002176121 *
E. GREN ET AL: "Novel leukocyte interferon subtype and structural comparison of alpha interferon genes", JOURNAL OF INTERFERON RESEARCH, vol. 4, 1984, pages 609 - 617, XP001016190 *
HENCO K ET AL: "STRUCTURAL RELATIONSHIP OF HUMAN INTERFERON ALPHA GENES AND PSEUDOGENES", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 185, no. 2, 20 September 1985 (1985-09-20), pages 227 - 260, XP000605295, ISSN: 0022-2836 *
SCAROZZA A M ET AL: "DNA SYNTHESIS IN NUCLEI ISOLATED FROM DAUDI B CELLS: A MODEL TO STUDY THE ANTIPROLIFERATIVE MECHANISMS OF INTERFERON-ALPHA", JOURNAL OF INTERFERON RESEARCH, MARY ANN LIEBERT, INC., NEW YORK, NY, US, vol. 12, 1992, pages 35 - 42, XP001002244, ISSN: 0197-8357 *

Also Published As

Publication number Publication date
AR025969A1 (es) 2002-12-26
MXPA02003492A (es) 2002-08-20
CN1451045A (zh) 2003-10-22
JP2003511031A (ja) 2003-03-25
CA2385045A1 (fr) 2001-04-12
WO2001025438A2 (fr) 2001-04-12
EP1238082A2 (fr) 2002-09-11
AU8001300A (en) 2001-05-10

Similar Documents

Publication Publication Date Title
WO2001025438A3 (fr) Homologues d'interferons alpha
WO2001075087A3 (fr) Variantes de lasubtilisine
WO2000023472A3 (fr) Proteines de fusion a interferon beta et leurs utilisations
WO1996034107A3 (fr) Proteines antivirales, sequences d'adn codant pour ces proteines et utilisations
EP1260587A3 (fr) Tyrosyl-tRNA-Synthetase
WO1999031236A3 (fr) ADNc PROLONGES POUR PROTEINES SECRETEES
CA2294516A1 (fr) Proteines ikk-.beta., acides nucleiques et procedes
WO2002006457A3 (fr) Genes de lipase
WO1999045098A3 (fr) Apport de proteines a des cellules eucaryotes au moyen de la yersinia recombinee
WO1998058957A3 (fr) Analogues d'hormones glycoproteiques a liaison reticulee disulfite, preparation et utilisation
WO2002059315A3 (fr) Nouveaux acides nucleiques et polypeptides et procedes de leur utilisation
CA2294566A1 (fr) Proteines ikk-.alpha., acides nucleiques et procedes
WO1998057983A3 (fr) Proteine de mammifere de type facteur de croissance nerveuse
WO2000018909A3 (fr) Acides nucleiques et proteines provenant de cenarchaeum symbiosum
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
WO1999013075A3 (fr) Genes humains regules par le cytomegalovirus humain et l'interferon
WO2001019870A3 (fr) POLYPEPTIDES SUBUNITAIRES DE CANAL CALCIUM α2δ-2, α2δ-3 OU α2δ-4 SOLUBLES SECRETES, ET ESSAIS DE RECHERCHE SYSTEMATIQUE UTILISANT CES POLYPEPTIDES
WO1999022005A3 (fr) D-glucosaminyle 3-o-sulfotransferases de sulfate d'heparane et utilisations associees
EP0897011A3 (fr) Arginine deiminase
WO2001040257A3 (fr) Polypeptides cytokines et acides nucleiques
DK0665890T3 (da) Forøget produktion af udskilte proteiner med rekombinante eukaryotiske celler
WO2001064912A3 (fr) Enzymes de degradation de triazine
AU1141695A (en) Interferon-alpha/beta binding protein, its preparation and use
WO2002062964A3 (fr) Variants d'amine oxydase ap1
WO2004089973A3 (fr) Peptides, polypeptides et proteines d'immunogenicite reduite et leurs procedes de production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2385045

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 80013/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003492

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 528590

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/643/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2000970665

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008167133

Country of ref document: CN

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000970665

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000970665

Country of ref document: EP